Commentary|Articles|March 9, 2015
An Open-Label Extension of SELECT
Author(s)Lori J. Wirth, MD
Lori J. Wirth, MD, discusses an open-label extension of the phase III SELECT trial, which looked at lenvatinib versus placebo for differentiated thyroid cancer.
Advertisement
Clinical Pearls
Lori J. Wirth, MD, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, assistant professor, Harvard Medical School, discusses an open-label extension of the phase III SELECT trial, which looked at lenvatinib versus placebo for the treatment of patients with relapsed/refractory differentiated thyroid cancer.
- In SELECT, median PFS was 18.3 months with lenvatinib and 3.6 months with placebo.
- In the open-label extension, PFS was slightly lower (12.4 months). The overall response rate was 54.9%.
- The best time to initiate treatment in RAI-refractory patients is unknown.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Clears Pen Device for Interferon Therapy in Polycythemia Vera
2
FDA Rejects Edotreotide PET Imaging Kit Over Manufacturing Concerns
3
Deep Responses Support Push for CAR T-Cell Therapy in AL Amyloidosis
4
FDA Accepts RP1 BLA Resubmission for Advanced Melanoma
5